Study of TRX-920 for Patients With Advanced Solid Tumors

The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that directly contains SN38 instead of Irinotecan. A series of biology and animal studies have demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects compared to Irinotecan.

NCT Number	NCT06143774
Lead Sponsor	TaiRx, Inc.
Conditions	Advanced Solid Tumor
Enrollment	30 participants
Start Date	2023-10-31
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-13